Biomedical Engineering Reference
In-Depth Information
interleukin-6 trans-signaling antagonist sgp130. J. Biol.
Chem. 283, 27200-27207.
96. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J.
(2011) The soluble Interleukin 6 receptor: generation and role
in inflammation and cancer. Eur. J. Cell Biol. 90, 484-494.
97. Melton L, Coombs A. (2008) Actemra poised to launch IL-6
inhibitors. Nat. Biotechnol. 26, 957-959.
98. Ding C, Cicuttini F, Li J, Jones G. (2009) Targeting IL-6 in the
treatment of inflammatory and autoimmune diseases. Expert
Opin. Investig. Drugs 18, 1457-1466.
99. Bush KA, Farmer KM, Walker JS, Kirkham BW. (2002)
Reduction of joint inflammation and bone erosion in rat
adjuvant arthritis by treatment with interleukin-17 receptor
IgG1 Fc fusion protein. Arthritis Rheum. 46, 802-805.
100. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L,
Coenen-de Roo CJ, Kolls JK, et al. (2001) IL-1-independent
role of IL-17 in synovial inflammation and joint
destruction during collagen-induced arthritis. J. Immunol.
167, 1004-1013.
101. Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters
MJ, et al. (2008) The human IL-17F/IL-17A heterodimeric
cytokine signals through the IL-17RA/IL-17RC receptor
complex. J. Immunol. 181, 2799-2805.
102. Lubberts E. (2008) IL-17/Th17 targeting: on the road to
prevent chronic destructive arthritis? Cytokine 41, 84-91.
103. Korn T, Bettelli E, Oukka M, Kuchroo VK. (2009) IL-17 and
Th17 Cells. Annu. Rev. Immunol. 27, 485-517.
104. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum
K, et al. (2007) Identification of the IL-17 receptor related
molecule IL-17RC as the receptor for IL-17F. J. Immunol.
179, 5462-5473.
105. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, et al.
(2001) Identification of a novel receptor for B lymphocyte
stimulator that is mutated in a mouse strain with severe B cell
deficiency. Curr. Biol. 11, 1547-1552.
106. Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K,
Sa S, et al. (2006) A soluble BAFF antagonist, BR3-Fc,
decreases peripheral blood B cells and lymphoid tissue
marginal zone and follicular B cells in cynomolgus monkeys.
Am. J. Pathol. 168, 476-489.
107. Fleischmann R, Wei N, Shaw M, Birbara C, Anand B,
Gujrathi S, et al. (2006) BR3-Fc phase i study: safety,
pharmacokinetics (PK) and pharmacodynamic (PD) effects
of a novel BR3-Fc fusion protein in patients with rheumatoid
arthritis. Arthritis Rheum. 54, S229-S230.
108. Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore
M, et al. (2000) Recombinant CD4-IgG2 in human immuno-
deficiency virus type 1-infected children: phase 1/2 study.
The Pediatric AIDS Clinical Trials Group Protocol 351 Study
Team. J. Infect. Dis. 182, 1774-1779.
109. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT,
Dunstan CR. (2001) The effect of a single dose of osteopro-
tegerin in postmenopausal women. J. Bone Miner. Res. 16,
348-360.
110. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS,
Luthy R, et al. (1997) Osteoprotegerin: a novel secreted
protein involved in the regulation of bone density. Cell 89,
309-319.
111. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K,
Fujise N, et al. (1998) Identity of osteoclastogenesis inhibi-
tory factor (OCIF) and osteoprotegerin (OPG): a mechanism
by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Endocrinology 139, 1329-1337.
112. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand
JP, et al. (2003) A phase I study of AMGN-0007, a recombi-
nant osteoprotegerin construct, in patients with multiple
myeloma or breast carcinoma related bone metastases.
Cancer 97, 887-892.
113. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM.
(2005) Recombinant osteoprotegerin for juvenile Paget's
disease. N. Engl. J. Med. 353, 918-923.
114. Schwarz EM, Ritchlin CT. (2007) Clinical development of
anti-RANKL therapy. Arthritis Res. Ther. 9(Suppl. 1), S7.
115. Ng KW. (2009) Future developments in osteoporosis therapy.
Endocr Metab Immune Disord Drug Targets 9, 371-384.
116. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J,
Nohe A. (2011) Bone morphogenetic proteins: a critical
review. Cell. Signal. 23, 609-620.
117. Wang X, Lupardus P, Laporte SL, Garcia KC. (2009) Struc-
tural biology of shared cytokine receptors. Annu. Rev. Immu-
nol. 27, 29-60.
118. Shen MM, Schier AF. (2000) The EGF-CFC gene family in
vertebrate development. Trends Genet. 16, 303-309.
119. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK.
(2006) The structural basis of TGF-beta, bone morphoge-
netic protein, and activin ligand binding. Reproduction 132,
179-190.
120. Bier E. (2008) Intriguing extracellular regulation of BMP
signaling. Dev. Cell 15, 176-177.
121. Angers S, Moon RT. (2009) Proximal events in Wnt signal
transduction. Nat. Rev. Mol. Cell Biol. 10, 468-477.
122. Glinka Y, Stoilova S, Mohammed N, Prud'homme GJ. (2011)
Neuropilin-1 exerts co-receptor function for TGF-beta-1 on
the membrane of cancer cells and enhances responses to both
latent and active TGF-beta. Carcinogenesis 32, 613-621.
123. Davis S, Aldrich TH, Ip NY, Stahl N, Scherer S, Farruggella
T, et al. (1993) Released form of CNTF receptor alpha
component as a soluble mediator of CNTF responses. Science
259, 1736-1739.
124. Stahl N, Yancopoulos GD. (1993) The alphas, betas, and
kinases of cytokine receptor complexes. Cell 74, 587-590.
125. Ibanez CF. (2010) Beyond the cell surface: new mechanisms
of receptor function. Biochem. Biophys. Res. Commun. 396,
24-27.
126. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda
T, et al. (1989) Interleukin-6 triggers the association of its
receptor with a possible signal transducer, gp130. Cell 58,
573-581.
127. Economides AN, Ravetch JV, Yancopoulos GD, Stahl N.
(1995) Designer cytokines: targeting actions to cells of
choice. Science 270, 1351-1353.
Search WWH ::
Custom Search